Slide 1: First Quarter 2024 Financial Results & Business Update
First Quarter 2024 Financial Results & Business Update May 1, 2024 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkerm
Slide 3: Q1 2024 Financial and Operational Performance
Q1 2024 Financial and Operational Performance
Slide 4: Q1 2024 Financial Results Summary
In millions Q1 2024 Financial Results Summary Total Revenue In millions GAAP Net Income (Loss) GAAP Earnings (Loss) Per Share Diluted *Reflects reinstatement of certain U.S. royalties following the successful outcome of the Company’s arbitration with Janssen Pharmaceutica N.V. (“Janssen”), a subsidi
Slide 5: Q1 2024 Profitability From Continuing Operations
In millions Q1 2024 Profitability From Continuing Operations GAAP Net Income (Loss) From Continuing Operations In millions Non-GAAP Net Income* From Continuing Operations EBITDA* From Continuing Operations In millions *Reconciliation of this non-GAAP financial measure to the most directly comparable
Slide 6: Q1 2024 Revenue Summary
Q1 2024 Revenue Summary Amounts in the table above may not sum due to rounding. *Inclusive of ARISTADA INITIO® **Reflects reinstatement of certain U.S. royalties following the successful outcome of the Company’s arbitration with Janssen announced in June 2023. In millions, except % Q1’24 Q1’23 ∆ Q1’
Slide 7: Alkermes: 2024 Financial Expectations
Alkermes: 2024 Financial Expectations* *These expectations were initially provided by the Company on Feb. 15, 2024, are reiterated by the Company on May 1, 2024 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. ‡Reconcili
Slide 8: Q1 2024 Commercial Review
Q1 2024 Commercial Review
Slide 9: LYBALVI Performance and Expectations
LYBALVI® Performance and Expectations *These expectations were initially provided by the Company on Feb. 15, 2024, are reiterated by the Company on May 1, 2024 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. LYBALVI Qua
Slide 10: LYBALVI Prescription Growth Trends
LYBALVI® Prescription Growth Trends Q1’24 total TRx: ~49,600 reflecting 6% sequential growth compared to Q4’23 *Source: IQVIA NPA Weekly Post-Launch TRx* (Through 4/19/24) TRx Week
Slide 11: ARISTADA Performance and Expectations
ARISTADA® Performance and Expectations ARISTADA Quarterly Net Sales* ($M) Q1’24 ARISTADA net sales were $78.9M Inventory in the channel decreased by ~$3.6M during Q1’24 Outlook: FY’24 net sales expected to range from $340M – $360M†* *Inclusive of ARISTADA INITIO® † These expectations were initially
Slide 12: VIVITROL Performance and Expectations
VIVITROL® Performance and Expectations VIVITROL Quarterly Net Sales ($M) * These expectations were initially provided by the Company on Feb. 15, 2024, are reiterated by the Company on May 1, 2024 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaf
Slide 13: Business Update
Business Update
Slide 14: ALKS 2680: Investigational Oral Orexin Receptor Agonist for Narcolepsy
ALKS 2680: Investigational Oral Orexin 2 Receptor Agonist for the Once-Daily Treatment of Narcolepsy Upcoming Program Priorities NT1 Present additional phase 1b data at SLEEP 2024 – June Enroll Vibrance-1 phase 2 study NT2 Present phase 1b data at upcoming medical meeting Initiate phase 2 study (Vib
Slide 15: Vibrance-1 ALKS 2680 Phase 2 Study in Patients with NT1
Vibrance-1 ALKS 2680 Phase 2 Study in Patients with NT1: Recently Initiated Vibrance-1 Narcolepsy Type 1 Phase 2 Design 4 mg (n=20) 6 mg (n=20) 8 mg (n=20) Placebo (PBO) (n=20)
Slide 16: 2024 Strategic Priorities
2024 Strategic Priorities Driven by core products and streamlined operating structure Initiate phase 2 programs Advance internal development candidates and explore external pipeline opportunities Deliver strong commercial growth and profitability Advance orexin 2 receptor agonist program Expand neur
Slide 17: Appendix
Appendix
Slide 18: Appendix: Amounts Included in Discontinued Operations
Appendix: Amounts Included in Discontinued Operations (In thousands) Year Ended December 31, 2023 Three Months Ended March 31, 2024 Cost of goods manufactured and sold $ -- Research and development 2,516 Selling, general and administrative --- Income tax benefit $ (396) Loss from discontinued operat
Slide 19: Appendix: Financial Results GAAP to Non-GAAP Adjustments
Appendix: Financial Results GAAP to Non-GAAP Adjustments (In millions) Three Months Ended March 31, 2024 Three Months Ended March 31, 2023 Net Income (Loss) from Continuing Operations — GAAP $ 38.9 $ (12.1) Adjustments: Share-based compensation expense 32.8 21.0 Depreciation expense 7.0 9.4 Amortiza
Slide 20: Appendix: Financial Results GAAP to EBITDA Adjustments
Appendix: Financial Results GAAP to EBITDA Adjustments (In millions) Three Months Ended March 31, 2024 Three Months Ended March 31, 2023 Net Income (Loss) from Continuing Operations — GAAP $ 38.9 $ (12.1) Adjustments: Depreciation expense 7.0 9.4 Amortization expense 1.1 8.8 Interest income (9.4) (5
Slide 21: Appendix: 2024 Guidance GAAP to Non-GAAP Adjustments
Appendix: 2024 Guidance GAAP to Non-GAAP Adjustments (In millions, except per share data) Year Ended December 31, 2023 Year Ending December 31, 2024 Shares+ Earnings Per Share Projected Net Income — GAAP $ 370.0 173.0 $ 2.14 Adjustments: Share-based compensation expense 86.0 Depreciation expense 35.
Slide 22: Appendix: 2024 Guidance GAAP to EBITDA Adjustments
Appendix: 2024 Guidance GAAP to EBITDA Adjustments (In millions) Year Ended December 31, 2023 Year Ending December 31, 2024 Projected Net Income — GAAP $ 370.0 Adjustments: Net interest income (16.0) Depreciation expense 35.0 Amortization expense 1.0 Provision for income taxes 75.0 Projected EBITDA
Slide 23: www.alkermes.com
www.alkermes.com © 2024 Alkermes. All rights reserved.